# Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

> **NCT03225924** · PHASE1,PHASE2 · TERMINATED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 25 (actual)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** Entospletinib
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03225924
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-26
- **Primary completion:** 2019-10-18
- **Final completion:** 2019-10-18
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Stop of drug development
- **Last updated:** 2020-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03225924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03225924, "Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03225924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*